Our experts in the UK, Brussels and our European Alliance Network provide advice on EU/competition matters and disputes across a broad range of sectors.
Our competition team specialises in UK and EU competition law and related regulatory work. We can advise you on your merger clearance from the UK and other competition authorities, and often provide merger arbitrage advice for leading financial institutions.
We're experienced in acting on high-profile competition and dawn raid investigations, and deal with other sector regulators including ORR, Ofgem, the OFT and Ofcom. We also advise on day-to-day competition issues including commercial agreements and practices, compliance programmes and provide competition law training and audits.
We combine high-level expertise with practical commercial solutions to give a comprehensive service.
As part of the firm’s focus on Healthcare and Life Sciences, we sponsored the EU Pharma Law Forum for the second year running. The conference, held in Brussels in May 2016 and organised by Informa is Europe's leading pharmaceutical law conference, providing critical guidance on competition law, patent litigation, regulation (safety, clinical trials etc.), data privacy and licensing agreements in the pharmaceutical industry. Partner Brian Sher and consultant Ashley Roughton were speakers.
Brian presented on discounts, rebates and excessive pricing in the pharmaceutical industry – click here to access his slides and here to access his accompanying note. Ashley spoke on accountability and record-keeping in a pharma context – click here to access his slides. Ashley also circulated a paper on a topical issue concerning "second medical use" patents. Click here to view.
This is an editorial published by Brian Sher in the April 2015 issue of the Journal of European Competition Law and Practice. It is part of a dialogue on how the Court of Justice of the EU should respond to a very restrictive judgment on exclusivity rebates produced by the EU General Court in 2014. The issues have serious ramifications for dominant firms and those that trade with them.